Tandem Diabetes Care Inc (NASDAQ:TNDM) EVP Sells $930,150.00 in Stock

Tandem Diabetes Care Inc (NASDAQ:TNDM) EVP Brian B. Hansen sold 15,000 shares of Tandem Diabetes Care stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $62.01, for a total value of $930,150.00. Following the transaction, the executive vice president now owns 17,991 shares of the company’s stock, valued at $1,115,621.91. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Shares of NASDAQ TNDM opened at $57.36 on Friday. The company has a current ratio of 2.46, a quick ratio of 2.21 and a debt-to-equity ratio of 0.09. Tandem Diabetes Care Inc has a 12 month low of $26.40 and a 12 month high of $74.81. The stock has a 50 day moving average of $60.42 and a 200-day moving average of $63.80. The company has a market capitalization of $3.42 billion, a P/E ratio of -22.49 and a beta of 0.16.

Several brokerages have recently commented on TNDM. Guggenheim began coverage on Tandem Diabetes Care in a research note on Thursday, October 17th. They set a “buy” rating and a $76.00 target price for the company. ValuEngine upgraded Tandem Diabetes Care from a “hold” rating to a “buy” rating in a research note on Friday, November 1st. Oppenheimer lifted their target price on Tandem Diabetes Care from $80.00 to $84.00 in a research note on Friday, August 2nd. Robert W. Baird reduced their target price on Tandem Diabetes Care from $81.00 to $71.00 and set an “outperform” rating for the company in a research note on Tuesday. Finally, BidaskClub downgraded Tandem Diabetes Care from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $76.54.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC boosted its stake in Tandem Diabetes Care by 53.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 460 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 160 shares during the period. TRUE Private Wealth Advisors bought a new stake in Tandem Diabetes Care in the 2nd quarter valued at $33,000. First Quadrant L P CA bought a new stake in Tandem Diabetes Care in the 3rd quarter valued at $34,000. James Investment Research Inc. boosted its stake in Tandem Diabetes Care by 15.9% in the 2nd quarter. James Investment Research Inc. now owns 1,315 shares of the medical device company’s stock valued at $85,000 after purchasing an additional 180 shares during the period. Finally, Stephens Inc. AR bought a new stake in Tandem Diabetes Care in the 2nd quarter valued at $113,000. Institutional investors and hedge funds own 80.49% of the company’s stock.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Read More: What is meant by holder of record?

Insider Buying and Selling by Quarter for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.